These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 32381512)
1. Improving response to progestin treatment of low-grade endometrial cancer. Baxter E; Brennan DJ; McAlpine JN; Mueller JJ; Amant F; van Gent MDJM; Huntsman DG; Coleman RL; Westin SN; Yates MS; Krakstad C; Quinn MA; Janda M; Obermair A Int J Gynecol Cancer; 2020 Nov; 30(11):1811-1823. PubMed ID: 32381512 [TBL] [Abstract][Full Text] [Related]
2. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series. Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524 [TBL] [Abstract][Full Text] [Related]
4. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis. Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311 [TBL] [Abstract][Full Text] [Related]
5. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723 [TBL] [Abstract][Full Text] [Related]
7. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307 [TBL] [Abstract][Full Text] [Related]
8. [Fertility-preserving treatment outcomes in endometrial cancer and atypical hyperplasia patients with different molecular profiles]. Shao WY; Dong YT; Lyu QY; Liao JB; Xue Y; Chen XJ Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):742-754. PubMed ID: 37849255 [No Abstract] [Full Text] [Related]
9. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review. Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F Acta Obstet Gynecol Scand; 2019 Sep; 98(9):1086-1099. PubMed ID: 30793281 [TBL] [Abstract][Full Text] [Related]
10. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment. Peng H; Jiang J; Li L; Hao Z; Lian H; Du H; Wang W Gynecol Oncol; 2024 Jul; 186():154-160. PubMed ID: 38691985 [TBL] [Abstract][Full Text] [Related]
11. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012 [TBL] [Abstract][Full Text] [Related]
12. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer. Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Baker J; Obermair A; Gebski V; Janda M Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499 [TBL] [Abstract][Full Text] [Related]
14. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen. Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091 [TBL] [Abstract][Full Text] [Related]
15. Brusatol sensitizes endometrial hyperplasia and cancer to progestin by suppressing NRF2-TET1-AKR1C1-mediated progestin metabolism. Hu M; Sun D; Yu J; Fu Y; Qin Z; Huang B; Zhang Q; Chen X; Wei Y; Zhu H; Wang Y; Feng Y; Zheng W; Liao H; Li J; Wu S; Zhang Z Lab Invest; 2022 Dec; 102(12):1335-1345. PubMed ID: 36038734 [TBL] [Abstract][Full Text] [Related]
16. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gunderson CC; Fader AN; Carson KA; Bristow RE Gynecol Oncol; 2012 May; 125(2):477-82. PubMed ID: 22245711 [TBL] [Abstract][Full Text] [Related]
17. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Penner KR; Dorigo O; Aoyama C; Ostrzega N; Balzer BL; Rao J; Walsh CS; Cass I; Holschneider CH Gynecol Oncol; 2012 Mar; 124(3):542-8. PubMed ID: 22079678 [TBL] [Abstract][Full Text] [Related]
18. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis. Shao F; Li Y; Zhao Y Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671 [TBL] [Abstract][Full Text] [Related]
19. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383 [TBL] [Abstract][Full Text] [Related]
20. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]